AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38720383 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety and tolerability endpoints
Number of subjects: 0
Study 38720383 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 0
Study 38720661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cafedrine/theodrenaline (C/T) combination (20:1)
Number of subjects: 315
Study 38720697 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring group (n=178)
Number of subjects: 695
Study 38720697 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer group (n=155)
Number of subjects: 695
Study 38720697 — intervention group
Group type: EXPERIMENTAL
Intervention: Autumn group (n=182)
Number of subjects: 695
Study 38720697 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter group (n=180)
Number of subjects: 695
Study 38720697 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of MACE across all groups
Number of subjects: 695
Study 38720913 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week low-frequency rTMS targeting the right dorsolateral prefrontal cortex (rDLPFC) + treatment as usual (TAU) (n = 25)
Number of subjects: 50
Study 38720913 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation + treatment as usual (TAU) (n = 25)
Number of subjects: 50
Study 38720913 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only (for low FCR group)
Number of subjects: 50
Study 38720913 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment fMRI scan
Number of subjects: 50
Study 38721015 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by liver transplantation (LT)
Number of subjects: 157
Study 38721015 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (C)
Number of subjects: 157
Study 38721015 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation (LT)
Number of subjects: 157
Study 38721358 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib 25 mg/m administered with a low-fat meal
Number of subjects: 24
Study 38721358 — intervention group
Group type: COMPARATOR
Intervention: Selumetinib 25 mg/m administered in a fasted state
Number of subjects: 24
Study 38721402 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacnotuzumab (MCS110) in combination with Spartalizumab (PDR001)
Number of subjects: 8
Study 38721639 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Body Project (DBP)
Number of subjects: 280
Study 38721639 — intervention group
Group type: COMPARATOR
Intervention: Educational control
Number of subjects: 280
Study 38721650 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised methadone
Number of subjects: 269
Study 38721650 — intervention group
Group type: COMPARATOR
Intervention: Flexible take-home dosing buprenorphine/naloxone
Number of subjects: 269
Study 38721680 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral preparation of hyaluronic acid, chondroitin sulfate, N-acetylglucosamine, and vitamin C once a day for 3 months
Number of subjects: 50
Study 38721680 — intervention group
Group type: COMPARATOR
Intervention: Control group received an oral preparation of cranberry, D-mannose, propolis extract, turmeric, and Boswellia twice a day for 3 months
Number of subjects: 50
Study 38721977 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated vertebral fracture assessment using chest CT
Number of subjects: 3231
Study 38721977 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated vertebral segmentation module
Number of subjects: 3231
Study 38721977 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated vertebral labelling module
Number of subjects: 3231
Study 38721977 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated vertebral segmentation for low dose CT
Number of subjects: 3231
Study 38721977 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture assessment from low dose CT
Number of subjects: 3231
Study 38722221 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab first-line maintenance therapy
Number of subjects: 79
Study 38722325 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NT-proBNP concentrations in the Explorys cohort (median 1250 pg/mL)
Number of subjects: 259
Study 38722325 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NT-proBNP concentrations in the PCMR cohort (median 184 pg/mL)
Number of subjects: 259
Study 38722346 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game with the REAplan
Number of subjects: 0
Study 38722461 — intervention group
Group type: COMPARATOR
Intervention: Normal renal function (GFR ≥ 90 mL/min)
Number of subjects: 83
Study 38722461 — intervention group
Group type: COMPARATOR
Intervention: Normal hepatic function
Number of subjects: 83
Study 38722537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen
Number of subjects: 50
Study 38722621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib (30 mg/d) with reduced-intensity chemotherapy, followed by single-agent ponatinib after cycle 20.
Number of subjects: 232
Study 38722621 — intervention group
Group type: COMPARATOR
Intervention: Imatinib (600 mg/d) with reduced-intensity chemotherapy, followed by single-agent imatinib after cycle 20.
Number of subjects: 232
Study 38722621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib (30 mg/d)
Number of subjects: 232
Study 38722621 — intervention group
Group type: COMPARATOR
Intervention: Imatinib (600 mg/d)
Number of subjects: 232
Study 38722621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib
Number of subjects: 232
Study 38722621 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 232
Study 38722641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab induction (240 mg every 2 weeks)
Number of subjects: 169
Study 38722641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + ipilimumab (3 mg/kg + 1 mg/kg, followed by 1 mg/kg + 3 mg/kg)
Number of subjects: 169
Study 38722641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + ipilimumab (1 mg/kg + 3 mg/kg)
Number of subjects: 169
Study 38722641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + ipilimumab (high-dose)
Number of subjects: 169
Study 38722644 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan monthly (15 mg per 0.1-mL intravitreal injection)
Number of subjects: 936
Study 38722644 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan every other month (15 mg per 0.1-mL intravitreal injection)
Number of subjects: 936
Study 38722644 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan monthly vs pegcetacoplan every other month
Number of subjects: 936
Study 38722644 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (monthly or every other month)
Number of subjects: 936
Study 38722664 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) at 0.6 mg/m2 on day 8 and day 15 of a 28-day cycle combined with DA-EPOCH
Number of subjects: 24
Study 38722664 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) combined with DA-EPOCH
Number of subjects: 24
Study 38722831 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit Less program (12-week intervention including goal-setting session, Fitbit, smart water bottle, weekly text messages)
Number of subjects: 70
Study 38722831 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit Less program
Number of subjects: 70
Study 38722831 — intervention group
Group type: COMPARATOR
Intervention: American Heart Association's 'Answers by Heart' fact sheets
Number of subjects: 70
Study 38722838 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver (30 cmH2O for 30 s applied at three time points)
Number of subjects: 125
Study 38722838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alveolar recruitment maneuver)
Number of subjects: 125
Study 38722838 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver
Number of subjects: 125
Study 38722838 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study 38722926 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness and acceptance-based intervention (weekly 90-minute group sessions for four consecutive weeks)
Number of subjects: 122
Study 38722926 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care (control group)
Number of subjects: 122
Study 38723189 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist protocol with individualized fixed daily dose of follitropin delta
Number of subjects: 437
Study 38723189 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist protocol with individualized fixed daily dose of follitropin delta
Number of subjects: 437
Study 38723189 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist protocol
Number of subjects: 437
Study 38723189 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist protocol
Number of subjects: 437
Study 38723214 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally competent education and HPV self-sampling
Number of subjects: 40
Study 38723227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + relatlimab + chemotherapy
Number of subjects: 274
Study 38723227 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab + chemotherapy
Number of subjects: 274
Study 38723373 — intervention group
Group type: EXPERIMENTAL
Intervention: encorafenib 450 mg QD plus binimetinib 45 mg BID
Number of subjects: 577
Study 38723373 — intervention group
Group type: COMPARATOR
Intervention: vemurafenib 960 mg BID
Number of subjects: 577
Study 38723373 — intervention group
Group type: EXPERIMENTAL
Intervention: encorafenib monotherapy 300 mg QD
Number of subjects: 577
Study 38723593 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Laparoscopic Prostatectomy (RALP)
Number of subjects: 342
Study 38723593 — intervention group
Group type: COMPARATOR
Intervention: Open Radical Retropubic Prostatectomy
Number of subjects: 342
Study 38723617 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational gene therapies for RTT
Number of subjects: 0
Study 38723644 — intervention group
Group type: EXPERIMENTAL
Intervention: Maralixibat (starting dose 142.5 μg/kg, then escalated to 570 μg/kg)
Number of subjects: 93
Study 38723644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 38723644 — intervention group
Group type: EXPERIMENTAL
Intervention: Maralixibat
Number of subjects: 93
Study 38723650 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 1500
Study 38723858 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ShortMAC-F
Number of subjects: 114
Study 38723867 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic hepatectomy
Number of subjects: 3448
Study 38723867 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic hepatectomy
Number of subjects: 3448
Study 38723867 — intervention group
Group type: COMPARATOR
Intervention: Open hepatectomy
Number of subjects: 3448
Study 38723880 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-QCA-assisted PCI strategy
Number of subjects: 400
Study 38723880 — intervention group
Group type: COMPARATOR
Intervention: Optical coherence tomography-guided PCI strategy
Number of subjects: 400
Study 38723981 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod
Number of subjects: 616
Study 38723981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study 38724038 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite sleep health score
Number of subjects: 257
Study 38724038 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregularity (individual sleep dimension)
Number of subjects: 257
Study 38724038 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor satisfaction (individual sleep dimension)
Number of subjects: 257
Study 38724038 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower alertness (individual sleep dimension)
Number of subjects: 257
Study 38724038 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite sleep health scores and individual sleep dimensions
Number of subjects: 257
Study 38724058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injections of ICG twice with intraoperative assessment of anastomotic blood flow using the near-infrared NIR-ICG system during total mesorectal excision (TME) surgery.
Number of subjects: 712
Study 38724058 — intervention group
Group type: COMPARATOR
Intervention: Conventional TME surgery without the use of the NIR-ICG system.
Number of subjects: 712
Study 38724182 — intervention group
Group type: EXPERIMENTAL
Intervention: belimumab
Number of subjects: 0
Study 38724182 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 38724231 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus (STN) local field potentials (LFPs) recorded during NREM sleep
Number of subjects: 13
Study 38724231 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus (STN) local field potentials (LFPs)
Number of subjects: 13
Study 38724259 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 0
Study 38724261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Number of subjects: 120
Study 38724261 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RF)
Number of subjects: 120
Study 38724261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 38724266 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50
Study 38724266 — intervention group
Group type: COMPARATOR
Intervention: Total inhalational anaesthesia
Number of subjects: 50
Study 38724293 — intervention group
Group type: EXPERIMENTAL
Intervention: felcisetrag 0.5 mg daily
Number of subjects: 209
Study 38724293 — intervention group
Group type: EXPERIMENTAL
Intervention: felcisetrag 0.5 mg pre-surgery
Number of subjects: 209
Study 38724293 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 209
Study 38724408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad hoc procedures
Number of subjects: 101
Study 38724408 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned procedures
Number of subjects: 101
Study 38724408 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 101
Study 38724531 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer (18-to-20 month) regimen for MDR/RR TB
Number of subjects: 1286
Study 38724531 — intervention group
Group type: COMPARATOR
Intervention: Cavitary disease
Number of subjects: 1286
Study 38724531 — intervention group
Group type: COMPARATOR
Intervention: BMI < 18.5
Number of subjects: 1286
Study 38724531 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis C
Number of subjects: 1286
Study 38724531 — intervention group
Group type: COMPARATOR
Intervention: Prior treatment with second-line drugs
Number of subjects: 1286
Study 38724531 — intervention group
Group type: COMPARATOR
Intervention: Longer time to initial culture conversion
Number of subjects: 1286
Study 38724605 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine milk-derived human milk fortifier (HMF) with first feedings
Number of subjects: 52
Study 38724605 — intervention group
Group type: COMPARATOR
Intervention: Delayed fortification at 80 ml/kg/day
Number of subjects: 52
Study 38724605 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine milk-derived human milk fortifier (HMF)
Number of subjects: 52
Study 38724831 — intervention group
Group type: EXPERIMENTAL
Intervention: Holograms (HG)
Number of subjects: 52
Study 38724831 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography (CT) images
Number of subjects: 52
Study 38724841 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% gel (CAB)
Number of subjects: 363
Study 38724841 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel (control)
Number of subjects: 363
Study 38724874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment (AHT) targeting systolic blood pressure (SBP) ≤140 mmHg for a median duration of 7 weeks
Number of subjects: 14
Study 38724874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment (AHT)
Number of subjects: 14
Study 38724879 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassuring instructions
Number of subjects: 72
Study 38724879 — intervention group
Group type: COMPARATOR
Intervention: Control instructions
Number of subjects: 72
Study 38724879 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral instructions
Number of subjects: 72
Study 38724889 — intervention group
Group type: EXPERIMENTAL
Intervention: Weibull parametric model
Number of subjects: 491
Study 38724889 — intervention group
Group type: COMPARATOR
Intervention: Cox proportional hazards (CPH) model
Number of subjects: 491
Study 38724947 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 44
Study 38724947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 38724961 — intervention group
Group type: EXPERIMENTAL
Intervention: ØCD prevention program (six online group sessions incorporating CBT and ERP techniques)
Number of subjects: 0
Study 38724961 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 38724961 — intervention group
Group type: EXPERIMENTAL
Intervention: ØCD prevention program
Number of subjects: 0
Study 38724991 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecularly guided treatment (MGT) informed by molecular tumor boards (MTBs)
Number of subjects: 1000
Study 38724991 — intervention group
Group type: EXPERIMENTAL
Intervention: Tier 1: Therapeutic use of investigational drugs targeting genetic alterations (e.g., ALK, EGFR, ERBB2, BRAF, FH, ROS1, RET)
Number of subjects: 1000
Study 38724991 — intervention group
Group type: EXPERIMENTAL
Intervention: Tier 2: Drugs with approved indications or permitted for treatment outside of approved indications
Number of subjects: 1000
Study 38724991 — intervention group
Group type: EXPERIMENTAL
Intervention: Tier 3: Clinical trials matching the genetic alterations recommended by the MTB
Number of subjects: 1000
Study 38725194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraovarian PRP injection
Number of subjects: 83
Study 38725194 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 83
Study 38725258 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo D/C/F/TAF tablets
Number of subjects: 24
Study 38725258 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo D/C/TAF tablets
Number of subjects: 24
Study 38725287 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-subxiphoid robotic surgery using da Vinci SP platform for maximal thymectomy
Number of subjects: 15
Study 38725307 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprescribing intervention
Number of subjects: 0
Study 38725307 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 38725398 — intervention group
Group type: EXPERIMENTAL
Intervention: Relief drinking group
Number of subjects: 169
Study 38725398 — intervention group
Group type: COMPARATOR
Intervention: Reward drinking group
Number of subjects: 169
Study 38725985 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (Mel)
Number of subjects: 156
Study 38725985 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex)
Number of subjects: 156
Study 38725995 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose encorafenib 300 mg BID plus binimetinib 45 mg BID
Number of subjects: 13
Study 38725995 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose encorafenib 450 mg QD plus binimetinib 45 mg BID
Number of subjects: 13
Study 38725995 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated dose encorafenib 600 mg QD plus binimetinib 45 mg BID
Number of subjects: 13
Study 38726027 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BMI
Number of subjects: 75
Study 38726365 — intervention group
Group type: EXPERIMENTAL
Intervention: Batiraxcept in combination with durvalumab
Number of subjects: 11
Study 38726646 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored low-glycaemic index dietary educational intervention
Number of subjects: 166
Study 38726646 — intervention group
Group type: COMPARATOR
Intervention: General advice on a healthy diet (control group)
Number of subjects: 166
Study 38726850 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited Driving Pressure (LDP; ⩽15 cmH2O)
Number of subjects: 126
Study 38726850 — intervention group
Group type: COMPARATOR
Intervention: Low Tidal Volume (LTV)
Number of subjects: 126
Study 38726886 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 avocado per day for 6 months
Number of subjects: 134
Study 38726886 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet low in avocados
Number of subjects: 134
Study 38726892 — intervention group
Group type: COMPARATOR
Intervention: Shared decision-making (SDM) involving all components
Number of subjects: 64215
Study 38726892 — intervention group
Group type: COMPARATOR
Intervention: Abbreviated forms of SDM with clarification of values and preferences
Number of subjects: 64215
Study 38726892 — intervention group
Group type: COMPARATOR
Intervention: Enhanced communication about risks without other SDM aspects
Number of subjects: 64215
Study 38726920 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) concentration
Number of subjects: 98
Study 38726920 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 98
Study 38726920 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to the composite of clinically relevant arrhythmia, hospitalization for heart failure, or all-cause death
Number of subjects: 98
Study 38727191 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Number of subjects: 0
Study 38727191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38727516 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Regret Scale (DRS) survey 3-5 weeks post-PICU discharge
Number of subjects: 233
Study 38727516 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental Hispanic ethnicity
Number of subjects: 233
Study 38727516 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased PICU length of stay (LOS)
Number of subjects: 233
Study 38727516 — intervention group
Group type: EXPERIMENTAL
Intervention: Underlying respiratory disease
Number of subjects: 233
Study 38727649 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 700
Study 38727649 — intervention group
Group type: COMPARATOR
Intervention: OMT
Number of subjects: 700